Tafenoquine
Tafenoquine is a laboratory product developed by GlaxoSmithKline. It is an antimalarial agent used for research purposes.
Lab products found in correlation
4 protocols using tafenoquine
Comparison of Tafenoquine and Artemisinin Combinations
Tafenoquine Dose Randomized Placebo-Controlled Trial
Study schematic
Comparison of Tafenoquine and Primaquine Antimalarial Treatments
Tafenoquine versus Chloroquine for Malaria
There were to be two sequential cohorts: cohort 1 was 400 mg tafenoquine for three days and comparator; cohort 2 was planned to be tafenoquine 600 mg as a single dose and comparator, but was not executed because of slow parasite clearance in cohort 1.
Treatment allocation was based on a computer generated block randomization list (block size 6). Eligible patients were randomized to active treatment with either tafenoquine 400 mg for three days (GlaxoSmithKline, two 200 mg capsules per day); or chloroquine phosphate 1000 mg for two days (AstraZeneca UK Ltd, four 250 mg capsules per day; 600 mg chloroquine base) and chloroquine phosphate 500 mg for one day (two 250 mg capsules; 300 mg chloroquine base) followed by 15 mg primaquine base for 14 days (Muir Pty Ltd, one capsule per day, given with food). Matched placebos were given as shown in
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!